Crowdsourcing Adverse Events Associated With Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide Signaling for Migraine Prevention: Natural Language Processing Analysis of Social Media.

Autor: Zhang P; Department of Neurology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, United States., Kamitaki BK; Department of Neurology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, United States., Do TP; Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.; Department of Neurology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.; Danish Knowledge Center on Headache Disorders, Glostrup, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: JMIR formative research [JMIR Form Res] 2024 Nov 08; Vol. 8, pp. e58176. Date of Electronic Publication: 2024 Nov 08.

Safety and efficacy of biologic drugs in children or adolescents with atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.

Autor: Felix de Farias Santos AC; School of Pharmacy, City University of São Paulo, São Paulo, Brazil., Zamora FV; Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil., Galvao LKCS; Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil., Pimenta NDS; Faculty of Medicine, Federal University of the State of Do Rio de Janeiro, Rio de Janeiro, Brazil., Salles JPCEA; Faculty of Medicine, Federal University of the State of Do Rio de Janeiro, Rio de Janeiro, Brazil., Heffel KK; Department of Dermatology, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil.

Publikováno v: The Australasian journal of dermatology [Australas J Dermatol] 2024 Nov; Vol. 65 (7), pp. 550-559. Date of Electronic Publication: 2024 Aug 05.

Comparative safety of monoclonal antibodies in chronic inflammatory airway diseases (chronic sinusitis with nasal polyposis and asthma): A network meta-analysis.

Autor: Shen Y; Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China., Guan D; Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China., Gu Y; Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China., Zheng B; Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China., Ke X; Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China., Hong S; Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China., Yang Y; Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.

Publikováno v: International immunopharmacology [Int Immunopharmacol] 2024 Sep 10; Vol. 138, pp. 112462. Date of Electronic Publication: 2024 Jun 28.

SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.

Autor: Bloom N; Center for Vaccine Innovation, La Jolla Institute for Immunology., Ramirez SI; Center for Vaccine Innovation, La Jolla Institute for Immunology.; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Cohn H; Department of Microbiology.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York., Parikh UM; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania., Heaps A; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania., Sieg SF; Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio., Greninger A; Department of Medicine, University of Washington, Seattle., Ritz J; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Moser C; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Eron JJ; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine., Bajic G; Department of Microbiology., Currier JS; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Klekotka P; Eli Lilly and Company, San Diego., Wohl DA; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine., Daar ES; Lundquist Institute at Harbor, University of California, Los Angeles Medical Center, Torrance., Li J; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Hughes MD; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Chew KW; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Smith DM; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Crotty S; Center for Vaccine Innovation, La Jolla Institute for Immunology.; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Coelho CH; Department of Microbiology.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York.; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2024 Nov 15; Vol. 230 (5), pp. 1187-1196.

Safety and Effectiveness of Low-Density Lipoprotein Cholesterol-Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real-World, Postmarketing, Single-Arm Study.

Autor: Yokote K; Department of Endocrinology, Hematology and Gerontology Chiba University Graduate School of Medicine Chiba Japan., Ako J; Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan., Kitagawa K; Department of Neurology Tokyo Women's Medical University School of Medicine Tokyo Japan., Osada N; Medical Affairs Amgen K.K. Tokyo Japan., Sheng F; Medical Affairs Amgen K.K. Tokyo Japan., Sonoda M; Global Patient Safety Amgen K.K. Tokyo Japan., Teramoto T; Teikyo Academic Research Center Teikyo University Tokyo Japan.

Publikováno v: Journal of the American Heart Association [J Am Heart Assoc] 2024 Nov 05; Vol. 13 (21), pp. e035809. Date of Electronic Publication: 2024 Oct 29.